CY1107950T1 - Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι - Google Patents

Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι

Info

Publication number
CY1107950T1
CY1107950T1 CY20081100518T CY081100518T CY1107950T1 CY 1107950 T1 CY1107950 T1 CY 1107950T1 CY 20081100518 T CY20081100518 T CY 20081100518T CY 081100518 T CY081100518 T CY 081100518T CY 1107950 T1 CY1107950 T1 CY 1107950T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
navigation
vaccine compositions
neisseria
Prior art date
Application number
CY20081100518T
Other languages
English (en)
Inventor
Andrew Robinson
Andrew Richard Gorringe
Michael John Hudson
Philippa Bracegirdle
John Simon Kroll
Keith Cartwright
Steven Anthony Rochford Webb
Paul Richard Langford
Dwyer Cliona Anne O'
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904028.9A external-priority patent/GB9904028D0/en
Priority claimed from GBGB9922561.7A external-priority patent/GB9922561D0/en
Application filed by Health Protection Agency filed Critical Health Protection Agency
Publication of CY1107950T1 publication Critical patent/CY1107950T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Mεθόδοι και συνθέσεις για την αντιμετώπιση μικροβιακής μόλυνσης, και ειδικότερα μηνιγγοκοκκικής πάθησης, περιλαμβάνουν κοινοβιούντα Neisseria ή εκχύλισμα κοινοβιούντα Neisseria. Περαιτέρω μέθοδοι και συνθέσεις περιλαμβάνουν κοινοβιούντες Neisseria που εκφράζουν γονίδια από παθογόνα στελέχη του Neisseria και/ή ετερόλογα προϊόντα γονιδίου από μη νεϊσσεριακές πηγές. Τέτοιες συνθέσεις χρησιμοποιούνται σε παρασκευάσματα εμβολίου για την αντιμετώπιση μικροβιακής μόλυνσης.
CY20081100518T 1999-02-22 2008-05-19 Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι CY1107950T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9904028.9A GB9904028D0 (en) 1999-02-22 1999-02-22 Neisserial vaccine
GBGB9922561.7A GB9922561D0 (en) 1999-09-23 1999-09-23 Neisserial vaccine compositions and methods
EP00905182A EP1154791B1 (en) 1999-02-22 2000-02-22 Neisserial vaccine compositions and methods

Publications (1)

Publication Number Publication Date
CY1107950T1 true CY1107950T1 (el) 2013-09-04

Family

ID=26315168

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100518T CY1107950T1 (el) 1999-02-22 2008-05-19 Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι

Country Status (12)

Country Link
US (1) US7157245B2 (el)
EP (2) EP1852125A3 (el)
JP (1) JP4982009B2 (el)
AT (1) ATE386541T1 (el)
AU (1) AU779086B2 (el)
CA (1) CA2371928C (el)
CY (1) CY1107950T1 (el)
DE (1) DE60038099T2 (el)
DK (1) DK1154791T3 (el)
ES (1) ES2298128T3 (el)
PT (1) PT1154791E (el)
WO (1) WO2000050074A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2371928C (en) * 1999-02-22 2013-08-13 Microbiological Research Authority Neisserial vaccine compositions and methods
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
GB0007433D0 (en) * 2000-03-27 2000-05-17 Microbiological Res Authority Recombinant transferrin binding proteins
GB0107219D0 (en) * 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1374892A1 (en) * 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20070134214A1 (en) * 2003-08-13 2007-06-14 Feng Xu Inactivated host cell delivery of polynucleotides encoding immunogens
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2009262893B2 (en) 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB0916557D0 (en) 2009-09-21 2009-10-28 Health Prot Agency Commensal neisserial stress protein complexes
GB0922224D0 (en) 2009-12-21 2010-02-03 Hiltech Developments Ltd Transformation of commensal neisseria
WO2016036839A1 (en) * 2014-09-02 2016-03-10 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating gonorrhea
US10900043B2 (en) 2014-09-02 2021-01-26 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating bacterial disease
GB201522153D0 (en) * 2015-12-15 2016-01-27 Univ Southampton Meningococcal infection and modified neisseria lactamica
WO2020168146A1 (en) * 2019-02-14 2020-08-20 University Of Florida Research Foundation, Inc. Honeybee commensal snodgrassella alvi vaccine against pathogenic neisseriaceae

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288617A (en) * 1984-10-31 1994-02-22 Commonwealth Scientific And Industrial Research Organization Method of producing an antigenic preparation
US6737521B1 (en) * 1990-05-11 2004-05-18 The Rockefeller University Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5470740A (en) * 1993-11-04 1995-11-28 Life Technologies, Inc. Cloned NsiI restriction-modification system
IL117483A (en) * 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
GB9811260D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
PL349041A1 (en) * 1998-12-02 2002-07-01 Univ Maryland Plasmid maintenance system for antigen delivery
US6413768B1 (en) * 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
CA2371928C (en) * 1999-02-22 2013-08-13 Microbiological Research Authority Neisserial vaccine compositions and methods
GB0130123D0 (en) * 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation

Also Published As

Publication number Publication date
CA2371928C (en) 2013-08-13
PT1154791E (pt) 2008-05-30
DE60038099D1 (de) 2008-04-03
US7157245B2 (en) 2007-01-02
WO2000050074A3 (en) 2000-12-28
AU779086B2 (en) 2005-01-06
EP1852125A2 (en) 2007-11-07
EP1154791B1 (en) 2008-02-20
EP1154791A2 (en) 2001-11-21
EP1852125A3 (en) 2010-09-22
AU2681100A (en) 2000-09-14
DK1154791T3 (da) 2008-06-16
WO2000050074A2 (en) 2000-08-31
JP2002537352A (ja) 2002-11-05
DE60038099T2 (de) 2009-02-19
JP4982009B2 (ja) 2012-07-25
ES2298128T3 (es) 2008-05-16
US20030026809A1 (en) 2003-02-06
CA2371928A1 (en) 2000-08-31
ATE386541T1 (de) 2008-03-15

Similar Documents

Publication Publication Date Title
CY1107950T1 (el) Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι
CY1110880T1 (el) Αντιγονα neisserial
DK1047784T3 (da) Neissera meningitidis-antigener
CY1106431T1 (el) Γονοκοκκικες πρωτεϊνες και νουκλεϊκα οξεα
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
NO980883L (no) Forbindelser og fremgangsmÕter for immunterapi og diagnose av tuberkulose
WO1998056901A3 (en) Live attenuated vaccines
DK1235589T3 (da) Præparater der omfatter neisseria meningitidis-antigener fra serogruppe B og C samt et yderligere antigen
WO2002034773A3 (en) Streptococcal genes
WO2002075507A3 (en) Anti-bacterial vaccine compositions
CY1107560T1 (el) Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο
NZ295877A (en) A vaccine comprising the helicobacter bacterium and its use
DK1146889T3 (da) Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407
NO20013101L (no) Ytre overflateproteiner, deres gener og deres anvendelse
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
PT1194450E (pt) Vacina inactivada contra a calicivirose felina
AU2010201539B2 (en) Anti-bacterial vaccine compositions
AP1679A (en) Outer surface proteins, their genes, and their use.